R_{16} is selected from hydrogen, alkyl optionally substituted with 1-8 halogens, cycloalkyl optionally substituted with 1 or 2 groups selected from -OH, $-NH_2$, alkyl, heterocycloalkyl, and $-CF_3$, cycloalkylalkyl, heterocycloalkyl optionally substituted with -OH or $-NH_2$, alkoxyalkyl, aryl optionally substituted with 1, 2 or 3 alkoxy, heterocycloalkylalkyl, heteroaryl, gem-dicycloalkylalkyl, and dialkylaminoalkyl;

R_{17}, when present, is $-CH_2-$ or -CH(OH)-;

each of A_1 or A_2 is N or C(H), wherein A_1 and A_2 can be the same or different, provided that A_1 can be substituted with R_4 only when A_1 is C(H), and provided that A_2 can be substituted with R_4 only when A_2 is C(H);

L_1 is selected from $-C(O)O-$, $-C(O)NH-$, $-C(O)NHSO_2-$, $-(CH_2)_nC(O)NH-$, $-(CH_2)_nNHC(O)-$, $-(CH_2)_mNH-$, $-(CH_2)_nSO_2NH-$, $-(CH_2)_nNHSO_2-$, $-(CH_2)_mC(O)-$, $-(CH_2)_mO-$, and $-(CH_2)_mNH-(CH_2)_n-$;

L_2 is $-C(O)-NH-R_3$, -CN, $-C(O)-N(CH_3)-OCH_3$, or $-C(O)-R_3$;

n is 0 or 1;

m is 0, 1 or 2; and

each p is independently 0, 1, 2, 3 or 4.

[0005b] In one aspect, there is provided a pharmaceutical composition comprising the compound as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent.

[0005c] In one aspect, there is provided the use of a compound as described herein, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.

[0005d] In one aspect, there is provided the use of a compound as described herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of breast cancer, CML, colorectal carcinoma, glioma, melanoma, multiple myeloma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cell carcinoma, small cell lung carcinoma, unfolded protein response, neurodegenerative disease, infectious disease, inflammatory disease, autoimmune disorder, stroke, ischemia, cardiac disorder, sepsis, fibrogenetic disorder and metabolic disease.

[0005e] In one aspect, there is provided the use of a compound as described herein, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of Alzheimer's disease (AD) or frontotemporal lobal dementia.

NAME
2-[(1-ethylpropyl)amino]-N4-{8-[5-(3-piperidin-1-ylpropanoyl)pyridin-2-yl]-8-azabicyclo[3.2.1]oct-3-endo-yl}benzene-1,4-dicarboxamide;
2-[(cyclopropylmethyl)amino]-N4-{8-[5-(piperidin-1-ylacetyl)pyridin-2-yl]-8-azabicyclo[3.2.1]oct-3-endo-yl}benzene-1,4-dicarboxamide;
N-[8-(5-acetylpyridin-2-yl)-8-azabicyclo[3.2.1]oct-3-endo-yl]-2,5-dimethylbenzene-1,4-dicarboxamide; and
2-[(cyclopropylmethyl)amino]-N4-{8-[5-(trifluoroacetyl)pyridin-2-yl]-8-azabicyclo[3.2.1]oct-3-endo-yl}benzene-1,4-dicarboxamide;
or a pharmaceutically acceptable salt of any of the above compounds.

18. A pharmaceutical composition comprising the compound according to any of claims 1-17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent.

19. Use of a compound according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.


20. Use of a compound according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of breast cancer, CML, colorectal carcinoma, glioma, melanoma, multiple myeloma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cell carcinoma, small cell lung carcinoma, unfolded protein response, neurodegenerative disease, infectious disease, inflammatory disease, autoimmune disorder, stroke, ischemia, cardiac disorder, sepsis, fibrogenetic disorder and metabolic disease.

21. The use according to claim 20, wherein the neurodegenerative disease is characterized by accumulation of hyperphosphorylated or mutated forms of the microtubule-associated protein Tau.

22. Use of a compound according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of Alzheimer's disease (AD) or frontotemporal lobal dementia.

23. The use according to claim 20, wherein the disease is an infection from negative strand RNA viruses, influenza virus, hepatitis B, hepatitis C or herpes simplex virus type 1.

24. A compound according to Formula II:



II

or a pharmaceutically acceptable salt thereof, wherein:

R_{1b} is selected from heteroaryl optionally substituted with 1, 2 or 3 groups selected from halogen, phenyl and alkyl;

R_2 is a phenyl or a heteroaryl that can contain 1, 2 or 3 heteroatoms, wherein the aryl or heteroaryl can be substituted with 1, 2 or 3 groups selected from alkyl, -OH, alkoxy, and halogen;


R_{3b} is selected from hydrogen, $-CF_3$, $-NH_2$, -OH, alkyl optionally substituted with 1, 2 or 3 R_{5b}, alkoxy, dialkylaminoalkyl, cycloalkyl optionally substituted with arylalkoxy, aryl optionally substituted with 1, 2 or 3 groups selected from halogen, alkyl, alkoxy, dialkylaminoalkoxy and heterocycloalkyl optionally substituted with alkyl or aryl, alkenyl, alkynyl, heterocycloalkyl optionally substituted with a group selected from alkyl, -C(O)O-alkyl and arylalkyl, arylalkyl optionally substituted with alkylheterocycloalkyl at any ring position of the aryl group, and heteroaryl;

R_{5b} is selected from halogen, cycloalkyl, heteroaryl optionally substituted with 1, 2 or 3 groups selected from halogen, alkyl and alkoxy, alkylthio, heterocycloalkyl optionally substituted with 1, 2, or 3 groups selected from alkyl, halogen, phenyl and oxo, aryl optionally substituted with 1, 2 or 3 groups selected from halogen, alkyl, alkoxy, dialkylaminoalkoxy and heterocycloalkyl optionally substituted with alkyl, alkoxy, dialkylamino, -OH, $-C(O)-NH_2$, $-C(O)-O-CH_3$, $-C(O)-N(H)(C_1-C_3)$alkyl, heteroarylamino optionally substituted with halogen and $-OCF_3$;

L_{2b} is $-C(O)-NH-R_{3b}$, -CN or $-C(O)-R_{3b}$; and

X is O or S.

25. The compound according to claim 24, wheren R_{1b} is



(O)

wherein:

A_3 is =N- or =CH-;

each R_{18} is independently selected from $-NH_2$, halogen and alkyl;

the (H) ring is a 5 or 6 membered heterocyclic ring fused to the two carbon atoms to which the (H) ring is attached, wherein the (H) ring contains 1, 2 or 3 heteroatoms selected from N, O or S; and

c is 0, 1 or 2.

26. The compound according to claim 25, wherein Formula (O) is selected from 1H-benzimidazole optionally substituted with 1 or 2 methyl groups, 1H-indole optionally substituted with 1 or 2 methyl groups, benzofuran, 3,4-dihydro-2H-chromenyl optionally substituted with 1 or 2 methyl groups, 2,3-dihydrobenzofuranyl optionally substituted with 1 or 2 methyl groups, 2,3-dihydro-1,4-benzodioxin-6-yl optionally substituted with 1 or 2 methyl groups, 1H-1,2,3-benzotriazole optionally substituted with 1, 2 or 3 methyl groups, 9H-purin-9-yl optionally substituted with 1 or 2 groups selected from halogen and amino, 1,3-benzothiazole optionally substituted with 1 or 2 methyl groups, and 2,3-dihydro-1-benzofuran optionally substituted with 1 or 2 methyl groups.

27. The compound according to Claim 24, wherein the compound of Formula II is selected from one of the following compounds:

1,4-dimethyl-N-(8-{5-[({(1S)-1-[4-(4-methylpiperazin-1-yl)phenyl]ethyl}amino)carbonyl]pyridin-2-yl}-8-azabicyclo[3.2.1]oct-3-endo-yl)-1H-benzimidazole-5-carboxamide;
N-(8-{5-[({(1S)-1-[4-(4-methylpiperazin-1-yl)phenyl]ethyl}amino)carbonyl]pyridin-2-yl}-8-azabicyclo[3.2.1]oct-3-endo-yl)-1,3-benzothiazole-5-carboxamide;
4-methyl-N-(8-{5-[({(1S)-1-[4-(4-methylpiperazin-1-yl)phenyl]ethyl}amino)carbonyl]pyridin-2-yl}-8-azabicyclo[3.2.1]oct-3-endo-yl)-1H-1,2,3-benzotriazole-5-carboxamide;

28. A pharmaceutical composition comprising the compound according any of claims 24-27, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent.

29. Use of a compound according to any of claims 24-27, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of breast cancer, CML, colorectal carcinoma, glioma, melanoma, multiple myeloma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cell carcinoma, small cell lung carcinoma, unfolded protein response, neurodegenerative disease, infectious disease, inflammatory disease, autoimmune disorder, stroke, ischemia, cardiac disorder, sepsis, fibrogenetic disorder, metabolic disease, infection from negative strand RNA viruses, influenza virus, hepatitis B, hepatitis C, and herpes simplex virus type 1.